Endometrial stromal sarcoma-A retropsective analysis of factors affecting recurrence

被引:15
作者
Agarwal, Reshu [1 ]
Rajanbabu, Anupama [1 ]
Nair, Indu R. [2 ]
Satish, Chandramouli [3 ]
Jose, Georgeena [4 ]
Unikrishnan, U. G. [5 ]
机构
[1] Amrita Vishwavidyapeetham, Amrita Inst Med Sci, Dept Gynecol Oncol, Kochi, Kerala, India
[2] Amrita Vishwavidyapeetham, Amrita Inst Med Sci, Dept Pathol, Kochi, Kerala, India
[3] Amrita Vishwavidyapeetham, Amrita Inst Med Sci, Dept Surg Oncol, Kochi, Kerala, India
[4] Amrita Vishwavidyapeetham, Amrita Inst Med Sci, Dept Med Res, Kochi, Kerala, India
[5] Amrita Vishwavidyapeetham, Amrita Inst Med Sci, Dept Biostat, Kochi, Kerala, India
关键词
ESS; HGESS; Cytoreductive surgery; Adjuvant treatment; Recurrence; UTERINE SARCOMAS; OVARIAN PRESERVATION; ADJUVANT TREATMENT; PROGNOSTIC-FACTORS; STAGE-I; TUMORS; MANAGEMENT; OUTCOMES; UTERUS;
D O I
10.1016/j.ejogrb.2017.07.011
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To assess the factors associated with disease free survival and overall survival in endometrial stromal sarcoma (ESS). Methods: This was a single institution retrospective analysis done at Amrita Institute of Medical Sciences. Records from January 2005 to October 2016 were analysed and 42 patients with ESS were identified. Clinicopathological, surgical management, adjuvant treatment and outcome data were collected. Disease free and overall survivals were analysed using Kaplan-Meier method and compared using log rank test. Results: Out of 38 patients included in analysis 28 (73.7%) had low grade ESS (LGESS) and 10 (26.3%) had high grade ESS (HGESS). The median follow up period was 28 months (range 1-110 months). The 5 year disease free survival (DFS) and overall survival (OS) for the entire cohort were 62.9 and 89.1% respectively. High grade ESS was significantly associated with recurrence on univariate analysis (p = 0.045). Complete staging surgery in both HGESS and LGESS and adjuvant treatment in HGESS and advanced stage LGESS (cohort 1) were associated with improved 5-year DFS of 90.9% (p < 0.001). Completion staging surgery in patients with initial incomplete surgery (cohort 3) was associated with improved 5-year DFS of 100% (p < 0.001). Complete Staging surgery but no adjuvant treatment in HGESS and advanced stage LGESS (cohort 2) was associated with significantly poor 2-year DFS of 20% (5-year DFS rate 0%; as all patients recurred within 27 months) (P < 0.001). Significantly reduced 5-year DFS rate of 25% (p < 0.001) was also seen in cases where initial incomplete surgery was not followed by complete staging and adjuvant treatment (cohort 4). Adjuvant treatment in HGESS was associated with improved 5-year DFS of 66.7% (p = 0.043). Resection of recurrent lesions were associated with improved meansurvival of 41.2 months. Conclusion: Incomplete surgery and no adjuvant treatment in ESS are associated with poor DFS. Complete staging surgery is associated with improved DFS. Resection of recurrent disease is associated with survival advantage. (C) 2017 Elsevier B.V. All rights reserved.
引用
收藏
页码:92 / 97
页数:6
相关论文
共 31 条
  • [1] Alagikiozidis I, 2015, INT J GYNECOL ONCOL, P61
  • [2] Endometrial stromal tumours revisited: an update based on the 2014 WHO classification
    Ali, Rola H.
    Rouzbahman, Marjan
    [J]. JOURNAL OF CLINICAL PATHOLOGY, 2015, 68 (05) : 325 - 332
  • [3] [Anonymous], WHO CLASSIFICATION T
  • [4] Low grade endometrial stromal sarcoma of uterine corpus, a clinico-pathological and survey study in 14 cases
    Ashraf-Ganjoei T.
    Behtash N.
    Shariat M.
    Mosavi A.
    [J]. World Journal of Surgical Oncology, 4 (1)
  • [5] Ovary and uterus-sparing procedures for low-grade endometrial stromal sarcoma: A retrospective study of 153 cases
    Bai, Huimin
    Yang, Jiaxin
    Cao, Dongyan
    Huang, Huifang
    Xiang, Yang
    Wu, Ming
    Cui, Quancai
    Chen, Jie
    Lang, Jinghe
    Shen, Keng
    [J]. GYNECOLOGIC ONCOLOGY, 2014, 132 (03) : 654 - 660
  • [6] Endometrial stromal sarcoma: Analysis of recurrence following adjuvant treatment
    Beck, Tiffany L.
    Singhal, Pankaj K.
    Ehrenberg, Hugh M.
    Rose, Peter G.
    Lele, Shashikant B.
    Krivak, Thomas C.
    McBee, William C., Jr.
    [J]. GYNECOLOGIC ONCOLOGY, 2012, 125 (01) : 141 - 144
  • [7] TREATMENT OF ENDOMETRIAL STROMAL TUMORS
    BERCHUCK, A
    RUBIN, SC
    HOSKINS, WJ
    SAIGO, PE
    PIERCE, VK
    LEWIS, JL
    [J]. GYNECOLOGIC ONCOLOGY, 1990, 36 (01) : 60 - 65
  • [8] Endometrial stromal sarcoma: a population-based analysis
    Chan, J. K.
    Kawar, N. M.
    Shin, J. Y.
    Osann, K.
    Chen, L-m
    Powell, C. B.
    Kapp, D. S.
    [J]. BRITISH JOURNAL OF CANCER, 2008, 99 (08) : 1210 - 1215
  • [9] Low-grade endometrial stromal sarcoma: hormonal aspects
    Chu, MC
    Mor, G
    Lim, CY
    Zheng, WX
    Parkash, V
    Schwartz, PE
    [J]. GYNECOLOGIC ONCOLOGY, 2003, 90 (01) : 170 - 176
  • [10] Uterine sarcomas: A review
    D'Angelo, Emanuela
    Prat, Jaime
    [J]. GYNECOLOGIC ONCOLOGY, 2010, 116 (01) : 131 - 139